Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Drugs in Pipeline
20
Phase 3 Programs
12
Upcoming Catalysts
10
Next Catalyst
Feb 1, 2026
11dStock performance and market intelligence
11 upcoming, 2 past
For Depressive disorder. NDA filing. Extracted from SEC filing: 8-K
SourcePrimary completion for VCA-894A trial (NCT07223632) in Charcot Marie Tooth Disease (CMT)
SourcePrimary completion for Trichostatin A trial (NCT07065773) in Onychomycosis of Toenail
SourceFor Non-24-Hour Sleep-Wake Disorder. NDA filing. Extracted from SEC filing: 8-K
SourcePrimary completion for Tradipitant trial (NCT06138613) in Motion Sickness
SourcePrimary completion for Tasimelteon trial (NCT04652882) in Sleep Wake Disorders
SourceFor gastroparesis. NDA filing. Extracted from SEC filing: 8-K
SourcePrimary completion for VSJ-110 trial (NCT07179055) in Dry Eye
SourceFor Non-24-hour sleep-wake disorder in the blind. sNDA filing. Extracted from SEC filing: 8-K
SourcePrimary completion for iloperidone trial (NCT07090161) in Hypertension
SourcePrimary completion for VQW-765 trial (NCT07221578) in Social Anxiety Disorder (SAD)
SourceMachine learning insights and smart money movement
Pending NDA/BLA submissions with predicted PDUFA dates
Clinical development programs and drug candidates
Tasimelteon Oral Suspension
Insomnia Disorder
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Autism Spectrum Disorder
Ziprasidone
Schizophrenia
Tasimelteon
Sleep Wake Disorders
Milsaperidone
Major Depressive Disorder (MDD)
iloperidone
Schizophrenia
Open Label Tradipitant
Idiopathic Gastroparesis
Imsidolimab high dose
Generalized Pustular Psoriasis
VQW-765
Performance Anxiety
20 mg VEC-162
Insomnia
VEC-162 20 mg
Primary Insomnia
Tradipitant
Motion Sickness
Imsidolimab
Acne Vulgaris
VLY-686 (Tradipitant)
Gastroparesis
VSJ-110
Dry Eye
Trichostatin A
Onychomycosis of Toenail
VLY-686
Treatment-resistant Pruritus Associated With Atopic Dermatitis
VSF-173
Excessive Somnolence
VCA-894A
Charcot Marie Tooth Disease (CMT)
VEC-162
Circadian Rhythm Sleep Disorders
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder | - |
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder | - |
Ziprasidone | Phase 3 | Schizophrenia | - |
Tasimelteon | Phase 3 | Sleep Wake Disorders | - |
Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | - |
iloperidone | Phase 3 | Schizophrenia | - |
Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis | - |
Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis | - |
VQW-765 | Phase 3 | Performance Anxiety | - |
20 mg VEC-162 | Phase 3 | Insomnia | - |
VEC-162 20 mg | Phase 3 | Primary Insomnia | - |
Tradipitant | Phase 3 | Motion Sickness | - |
Imsidolimab | Phase 2 | Acne Vulgaris | - |
VLY-686 (Tradipitant) | Phase 2 | Gastroparesis | - |
VSJ-110 | Phase 2 | Dry Eye | - |
Trichostatin A | Phase 2 | Onychomycosis of Toenail | - |
VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | - |
VSF-173 | Phase 2 | Excessive Somnolence | - |
VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) | - |
VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders | - |
Approvals, filings, and latest developments